FIGURE 6 from Synergy of EGFR and AURKA Inhibitors in <i>KRAS</i>-mutated Non–small Cell Lung Cancers

Signaling patterns in KRAS^mut NSCLC xenografts 6 or 24 hours after treatment with erlotinib or/and alisertib. Quantification of Western blot images for A549 (A) xenograft tumors. Data are presented as mean ± SEM, n = 3–6 mice. B, Summary for A549 xenografts shows significant changes in protein levels and activation after erlotinib+alisertib treatment, in reference to vehicle treated control group. C, Quantification of Western blots for H358 xenograft tumors. Primary Western blot data are shown in Supplementary Figs. S4 and S5. *, Significantly different from corresponding groups with P < 0.05; **, P < 0.01; or ***, P < 0.001. Color of asterisks indicates comparison groups as follows: red, to control; orange, combination to erlotinib; green, combination to alisertib, purple, alisertib to erlotinib. C, vehicle; E, erlotinib; A, alisertib; EA, erlotinib + alisertib.